Privium Fund Management B.V. Acquires 21,555 Shares of Biogen Inc. $BIIB

Privium Fund Management B.V. lifted its holdings in shares of Biogen Inc. (NASDAQ:BIIB) by 41.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 73,480 shares of the biotechnology company’s stock after purchasing an additional 21,555 shares during the quarter. Biogen accounts for 2.4% of Privium Fund Management B.V.’s holdings, making the stock its 12th largest position. Privium Fund Management B.V. owned 0.05% of Biogen worth $12,932,000 as of its most recent SEC filing.

Several other hedge funds also recently made changes to their positions in BIIB. WPG Advisers LLC increased its holdings in shares of Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company’s stock worth $26,000 after purchasing an additional 117 shares during the period. Accredited Wealth Management LLC increased its stake in Biogen by 1,233.3% in the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 185 shares during the last quarter. First Horizon Corp bought a new position in Biogen in the fourth quarter valued at approximately $30,000. WFA of San Diego LLC bought a new position in Biogen in the second quarter valued at approximately $32,000. Finally, GoalVest Advisory LLC bought a new position in Biogen in the fourth quarter valued at approximately $35,000. 87.93% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on BIIB shares. UBS Group raised shares of Biogen from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $185.00 to $225.00 in a research note on Wednesday, April 22nd. Mizuho lifted their price objective on shares of Biogen from $207.00 to $236.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Argus raised shares of Biogen to a “hold” rating in a research note on Thursday, April 9th. Sanford C. Bernstein decreased their price objective on shares of Biogen from $201.00 to $200.00 in a research note on Thursday, April 30th. Finally, Canaccord Genuity Group lifted their price objective on shares of Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a research note on Wednesday, April 1st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $214.23.

Insider Buying and Selling at Biogen

In other Biogen news, insider Priya Singhal sold 2,660 shares of the business’s stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the sale, the insider owned 8,043 shares of the company’s stock, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.18% of the company’s stock.

Biogen Stock Performance

NASDAQ BIIB opened at $189.13 on Wednesday. The firm’s fifty day moving average price is $184.46 and its two-hundred day moving average price is $176.82. The stock has a market cap of $27.92 billion, a PE ratio of 20.29, a PEG ratio of 1.62 and a beta of 0.19. Biogen Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $202.41. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.41 and a current ratio of 3.06.

Biogen (NASDAQ:BIIB) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The firm had revenue of $2.48 billion for the quarter, compared to analysts’ expectations of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company’s revenue was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, equities analysts expect that Biogen Inc. will post 14.41 EPS for the current fiscal year.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.